Physician profile
Kwame A Ennin
NPI 1194955328
$131,966.78
in general payments reported to CMS, 2019-2025
28 companies · $10K in 2025
The $10K reported for 2025 was more than what 76% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,025 · 2021: $1,095 · 2022: $20K · 2023: $46K · 2024: $33K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Education: $25K · Travel and Lodging: $11K · Food and Beverage: $6,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,312.50 |
| Education | $25,375.00 |
| Travel and Lodging | $10,585.27 |
| Food and Beverage | $6,034.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $59,892.96 | 2019-2025 | Oxford, Persona, Tapestry |
| Medical Device Business Services, INC. | $36,868.29 | 2021-2025 | Actis, Endurance, Emphasys |
| Pacira Therapeutics, INC. | $18,292.65 | 2019-2020 | |
| Depuy Synthes Products, INC. | $5,269.73 | 2022-2024 | Actis |
| Kyocera Medical Technologies, INC. | $4,997.17 | 2024 | |
| Depuy Synthes Sales INC. | $1,550.50 | 2022-2025 | Va-Lcp, Na, Monovisc |
| Medacta USA, INC. | $1,162.94 | 2024-2025 | Gmk Sphere |
| Stryker Corporation | $1,145.54 | 2019-2024 | Variax, Augment Injectable, Axsos |
| Orthalign INC | $420.27 | 2021-2025 | Orthalign Plus |
| Bone Support INC. | $370.40 | 2020-2024 | Cerament G, Ceramentbone Void Filler |
| Shalby Advanced Technologies, INC. | $360.47 | 2024-2025 | Consensus Hip System, Consensus Knee System, Cks - Vitalite |
| Bioventus LLC | $281.12 | 2023-2024 | Durolane, Durolane |
| Heron Therapeutics, INC. | $244.35 | 2024-2025 | Zynrelef |
| Corentec America INC | $200.76 | 2025 | Corentec |
| Innovation Technologies INC | $157.35 | 2023 | Irrisept |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Think Surgical, INC. | $135.47 | 2025 | |
| Glaxosmithkline, LLC. | $117.85 | 2024 | |
| Amgen INC. | $108.11 | 2024 | |
| Curonix LLC | $95.98 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Pharmaceuticals Incorporated | $61.48 | 2022-2024 | Zilretta, Iovera, Exparel |
| Convatec INC. | $60.66 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $54.07 | 2020-2023 | Euflexxa |
| Pylant Medical | $39.14 | 2025 | |
| Ethicon US, LLC | $18.49 | 2025 | Vistaseal, Stratafix |
| Smith+Nephew, INC. | $17.56 | 2023 | Pico 7 |
| Medtronic USA, INC. | $16.02 | 2019 | |
| Integra Lifesciences Corporation | $13.76 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Solventum Corporation | $13.69 | 2025 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwame Ennin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.